TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01480752

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no injection
Description: inject nothing after inferior alveolar injection and before root canal therapy
Study: NCT02392039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
Study: NCT02876055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single shot interscalene nerve block
Description: Peripheral regional anesthesia nerve block - Single shot interscalene nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous interscalene nerve block
Description: Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Infiltration Analgesia (LIA)
Description: Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
Study: NCT01920620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient weight loss counseling
Description: Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and troubleshooting via phone
Description: All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
Study: NCT03736538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gas
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Study: NCT02391844

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: Oxycodone with Acetaminophen Extended Release
Study: NCT02861027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPTHA
Description: The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPTHA
Description: The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FES and PPTHA
Description: The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
Study: NCT01606228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
Study: NCT02293473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCO Rapid
Description: LiDCO Rapid haemodynamic monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS-Bispectral Index Monitor
Description: Depth of anaesthesia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOS-Cerebral Oxygenation Monitor
Description: regional brain tissue oxygenation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Using standard of care
Study: NCT00373425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT01826916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-88 (ecallantide)
Description: solution for injection 10 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-88 (ecallantide)
Description: solution for injection 10 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-88 (ecallantide)
Description: solution for injection 10 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-88 (ecallantide)
Description: solution for injection 10 mg/mL
Study: NCT02276768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001 375 mg TID
Description: GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001 500 mg TID
Description: GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
Description: GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIC-1002 460 mg (equimolar to GIC-1001 500 mg)
Description: GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical and matching active drugs GIC-1001 and GIC-1001
Study: NCT01563458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: 120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: 60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
Study: NCT00471991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH T04769G
Description: The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol / dienogest (SH D00659 AF)
Description: The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
Study: NCT01293266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
Study: NCT00949728

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conjunctival autograft using fibrin glue
Description: Conjunctival autograft using fibrin glue in pterygium surgery
Study: NCT02601768

Intervention type: DEVICE
Intervention: Transcatheter closure of ASD II
Description: Transcatheter closure of ASD II performed in our center.
Study: NCT03900117

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: split-course radiotherapy
Description: Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
Study: NCT01731522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EF condition
Study: NCT02269631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Legume diet group
Description: about 1 1/2 cups of legumes included in lunch and dinner meals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet group
Description: no legumes in lunch or dinner meals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartpill
Description: to assess how long food takes to pass through the digestive system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartpill
Description: to assess how long food takes to pass through the digestive system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: legumes
Description: about 1 1/2 cups of legumes included in lunch and dinner meals
Study: NCT01253395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Daily supervised strength training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Daily supervised aerobic exercise.
Study: NCT02610270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 Gums
Description: 760 mg DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 Gums
Description: 1140 mg DHA
Study: NCT04664816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-3PUFAs Treatment
Description: Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Placebo orally, twice a day for at least 12 months.
Study: NCT02931292

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained.
Study: NCT00359619

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CervarixTM
Description: Subjects were administered three doses of HPV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV investigational vaccine GSK568893A, different formulations
Description: Subjects were administered three doses of HPV investigational vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV investigational vaccine GSK568893A, different formulations
Description: Subjects were administered three doses of HPV investigational vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV investigational vaccine GSK568893A, different formulations
Description: Subjects were administered three doses of HPV investigational vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV investigational vaccine GSK568893A, different formulations
Description: Subjects were administered three doses of HPV investigational vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV investigational vaccine GSK568893A, different formulations
Description: Subjects were administered three doses of HPV investigational vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV investigational vaccine GSK568893A, different formulations
Description: Subjects were administered three doses of HPV investigational vaccine
Study: NCT00693225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole/sodium bicarbonate
Description: Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/sodium bicarbonate
Description: Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
Study: NCT03893916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MEG - EEG HR
Description: MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools.
Study: NCT03042468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: 177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-HBED-CC
Description: 68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging
Study: NCT00587288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00876044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (AVE0005)
Description: Intravenous route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous route
Study: NCT01414231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
Study: NCT02452294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
Study: NCT03151564

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography Scan - 50% Dose Reduction
Description: Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography Scan - 70% Dose Reduction
Description: Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Deep Learning Image Reconstruction (DLIR)
Description: Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
Study: NCT00408421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03838952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal medicine
Description: Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
Study: NCT01197560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Suggested starting doses for Etoposide are:~100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles
Study: NCT03925480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg Oral Tablet x 4
Description: A single prophylactic dose of antibiotic given during labour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study: NCT01941667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Messages, Virtual Home Visits
Description: Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families.